19983-28-9
Chemical Structure
VPC-14228
- CAS No.: 19983-28-9
- Formula:C13H14N2OS
- Molecular Weight:246.33
IUPAC Name: 4-(4-phenylthiazol-2-yl)morpholine
InChIKey: MRNNJVNMXOZEQC-UHFFFAOYSA-N
SMILES: N1(C2=NC(C3=CC=CC=C3)=CS2)CCOCC1
Biological Activity:
VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD). VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer[1]
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VPC-14228 | 99.36% | VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD). VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.76
HY-131953Androgen receptor-IN-3 -
Similarity Score 0.68
HY-183747Antitrypanosomal agent 32 -
Similarity Score 0.66
HY-153129EP2 receptor antagonist-2 -
Similarity Score 0.63
HY-138572Fanetizole -
Similarity Score 0.63
HY-175939AR-V7 ligand-1 -
Similarity Score 0.62
HY-119167Lotifazole -
Similarity Score 0.62
HY-W027340ARM1 -
Similarity Score 0.61
HY-101420VUF10460 -
Similarity Score 0.61
HY-121488GP130 receptor agonist-1 -
Explore the MedChemAI to find more analogs